Table 2.
Clinical characteristics at baseline and follow-up.
| CIS/RRMS study cohort | Timepoints | ||
|---|---|---|---|
| Baseline | 24 weeks | 48 weeks | |
| EDSS, median (IQR) | 2.0 (1.5–3.5) N = 44 |
2.0 (1.0–3.5) N = 21 |
1.5 (0.0–2.0)*p
=
0.076
N = 42 |
| Relapse at timepoint, N | 39 (89%) | 2 (5%) | 1 (2%) |
| Steroid treatment at relapse, N (%) | 30 (68) | 2 (5) | 1 (2) |
| Cerebral MRI, N (%) | 44 (100) | 36 (82) | 42 (95) |
| With CELs, N (%) | 23 (52) | 3 (8) | 0 (0) |
| Number of CELs, median (IQR) | 1 (1–3) | 2 (1–5) | 0 |
| Spinal cord MRI, N (%) | 23 (52) | 8 (18) | 6 (14) |
| With CELs | 9 (39%) | 1 (13%) | 0 (0%) |
| Number of CELs, median (IQR) | 1 (1–3) | 1 | 0 |
| DMT, N (%) | 12 (27) | 40 (91) | 39 (89)*p < 0.001 |
| Platform therapies | 4 | 1 | 0 |
| Teriflunomide | 0 | 1 | 1 |
| Fingolimod | 3 | 2 | 2 |
| Alemtuzumab | 4 | 4 | 5 |
| Cladribine | 0 | 4 | 4 |
| Ocrelizumab | 0 | 1 | 1 |
| Rituximab | 1 | 7 | 10 |
| Dimethyl fumarate | 0 | 4 | 2 |
| Natalizumab | 0 | 16 | 14*p < 0.001 |
| None | 32 (73%) | 4 (9%) | 5 (11%) |
CIS: clinically isolated syndrome; RRMS: relapsing-remitting multiple sclerosis; CEL: contrast-enhancing lesion; EDSS: Expanded Disability Status Scale; DMT: disease-modifying treatment; MRI: magnetic resonance imaging; IQR: interquartile range.
*
Comparison to baseline.